Project Grant R43GM128549

This $2,784,578 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of a novel "bioactive immune-modulating nanodrug" for the treatment of sepsis. The principal investigator aims to create a multifunctional nanoplatform that can simultaneously capture inflammatory signals, block immune cell activation, deliver antibiotics, and inhibit hyperinflammation in...

This $1,165,298 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop novel nanopore- and click-chemistry-based approaches for rapid, culture-independent detection of sepsis-causing pathogens directly from blood samples within 2 hours. The project will engineer nanopore biosensors and multiplex click chemistry-amplified nanopore sensing to target proteomic biomarkers like outer...

This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $350,000 to Medosome Biotec LLC, a for-profit limited liability company, to evaluate the safety and therapeutic potential of the investigational drug dichloroacetate (DCA) for the treatment of sepsis. The key research activities supported by this 1-year award include conducting pharmacokinetic, safety, and efficacy experiments...

This $455,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) supports a research program to decrease pediatric sepsis mortality. The key products and services to be delivered include: Development of an AI-guided early sepsis identification tool to enable timely diagnosis and treatment. Conducting sepsis phenotyping and creating digital twin patient models to predict personalized...

This $418,750 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) aims to investigate the role of T cell receptor (TCR) activation in neonatal and pediatric sepsis. The research will use comparisons between human neonates with sepsis and pediatric/adult sepsis patients to understand how T cell memory and sepsis affect T cell-APC interactions and TCR activation. The study will also examine...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key products and services to be delivered include: Characterizing the mechanism of action of the lead antibody candidate S3D4,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,574,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Children's Hospital Corporation (doing business as Boston Children's Hospital). The grant, with a performance period of July 19, 2024 to May 31, 2029, supports research on "Armed Nanobodies as Anti-Infectives and Anti-Tumor Agents". Key activities include: Developing nanobody-based fusion constructs that...

This $305,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of a clinical decision support system (CDSS) called Sepsis FLO. The CDSS is designed to precisely guide blood volume diagnosis and treatment for sepsis patients. Key activities include: 1) Developing an alpha prototype of the CDSS through user-centered design; 2) Validating three functional...

This Project Grant award of $890,400 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to elucidate the mechanism by which trauma and hemorrhagic shock predispose patients to developing sepsis. The key objectives are to: Determine the mechanism by which the metabolite 12(S)-HETE upregulates the expression of the enzyme ALOX15, forming a positive feedback loop that increases 12(S)-HETE generation, macrophage death, and...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $298,646 to Anvil Diagnostics Inc., a minority-owned small business located in Cambridge, MA, is for the development of a rapid, ultra-sensitive, and multiplexed diagnostic test for detecting sepsis-causing pathogens in neonates. The proposed DNA-based technology aims to comprehensively identify and quantify a wide range of pathogens from small blood volumes in under 4 hours, a...